{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:43:10Z","timestamp":1777725790957,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:p>Metamizole sodium continues to be used extensively as an analgesic in Poland. This study was the first undertaken to quantify the incidence of agranulocytosis associated with metamizole sodium in Poland, and to compare the findings with those from other countries. Based on data obtained retrospectively from medical records covering the period 1997\u20132001 in six haematology centres representative of Poland as a whole, the crude estimate obtained was a rate of 0.2 cases per million person-days of use. This is the same order of magnitude as the value from an epidemiological study covering several countries (0.3\u20134.0).<\/jats:p>\n                  <jats:p>W Polsce w dalszym ci\u0105gu na du\u017c\u0105 skal\u0119 stosuje si\u0119 s\u00f3l sodow\u0105 metamizolu jako lek przciwb\u00f3lowy. Przeprowadzone badanie by\u0142o pierws\u017c\u0105 pr\u00f3b\u0105 ilo\u015bciowego ustalenia zwi\u0105zku pomi\u0119dzy wyst\u0105pieniem nowych przypadk\u00f3w agranulocytozy a stosowaniem soli sodowej metamizolu w Polsce \u00ed por\u00f3wnania rezultat\u00f3w badania z wynikami uzyskanymi w innych krajach. Na podstawie danych uzyskanych retrospektywnie, z historii chor\u00f3b obejmuj\u0105cych okres 1997\u20132001 z sze\u015bciu o\u015brodk\u00f3w hematologicznych b\u0119d\u0105cych reprezentacyjnymi dla calej Polski, uzyskana surowa ocena wynosi\u0142a 0.2 przypadki na milion osobo\/dni stosowania. Otrzymany rz\u0105d wielko\u015bci mie\u015b\u0107i si\u0119 w dolnym zakresie wynik\u00f3w bada\u0144 epidemiologicznych w innych krajach (0.3\u20134.0).<\/jats:p>","DOI":"10.1177\/147323000203000504","type":"journal-article","created":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T14:22:28Z","timestamp":1361974948000},"page":"488-495","source":"Crossref","is-referenced-by-count":26,"title":["The Incidence of Metamizole Sodium-Induced Agranulocytosis in Poland"],"prefix":"10.1177","volume":"30","author":[{"given":"S","family":"Maj","sequence":"first","affiliation":[{"name":"Institute of Haematology and Blood Transfusion, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Lis","sequence":"additional","affiliation":[{"name":"Carter-Lis Associates Ltd, Surrey, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2002,10,1]]},"reference":[{"key":"bibr1-147323000203000504","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380130077032"},{"key":"bibr2-147323000203000504","unstructured":"Kaufman DW, Kelly JP, Levy M, Shapiro S (eds): The Drug Etiology of Agranulocytosis and Aplastic Anemia. New York: Oxford University Press, 1991; pp186\u2013203"},{"key":"bibr3-147323000203000504","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1999.60.573"},{"key":"bibr4-147323000203000504","first-page":"449","volume":"3","author":"Heimpel H","year":"1988","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"bibr5-147323000203000504","unstructured":"Kaufman DW, Kelly JP, Levy M: The Drug Etiology of Agranulocytosis and Aplastic Anaemia. Monographs in Epidemiology and Biostatistics 1991, volume 18. New York: Oxford University Press, pp5\u20139, 102\u2013105, 296\u2013304"},{"key":"bibr6-147323000203000504","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-483X(01)00360-2"},{"key":"bibr7-147323000203000504","first-page":"449","volume":"3","author":"Hartl PW","year":"1988","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"bibr8-147323000203000504","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198600324-00006"},{"key":"bibr9-147323000203000504","doi-asserted-by":"publisher","DOI":"10.1007\/BF00278592"},{"key":"bibr10-147323000203000504","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1979.03300070019017"},{"key":"bibr11-147323000203000504","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00076-6"},{"key":"bibr12-147323000203000504","first-page":"21","volume":"25","author":"Levy M","year":"1988","journal-title":"Agents Actions Suppl"},{"key":"bibr13-147323000203000504","unstructured":"ICH Harmonised Tripartite Guideline: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Data elements for transmission of individual case safety reports. Recommended for adoption at step 4 of the ICH process on 17 July 1997 by the ICH Steering Committee. Available at www.ich.org\/ (accessed 2 September 2002)"},{"key":"bibr14-147323000203000504","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5875.339"},{"key":"bibr15-147323000203000504","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91779-3"},{"key":"bibr16-147323000203000504","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb01641.x"},{"key":"bibr17-147323000203000504","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1002\/(SICI)1099-1557(199703)6:2<115::AID-PDS252>3.0.CO;2-X","volume":"6","author":"Martinez C","year":"1997","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"bibr18-147323000203000504","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-0348-6387-2_4"},{"key":"bibr19-147323000203000504","volume-title":"Consolidated list of products whose consumption and or sale have been banned, withdrawn, severely restricted or not approved by Governments.","year":"1994"},{"key":"bibr20-147323000203000504","unstructured":"EEA National Regulatory Authorities: EU\/EEA Rapid Alert, 28 April 1998"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/147323000203000504","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/147323000203000504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:43:30Z","timestamp":1777459410000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/147323000203000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1177\/147323000203000504"],"URL":"https:\/\/doi.org\/10.1177\/147323000203000504","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}